Answers are grounded in this paper and cite their sources.
Most HIV-1 production occurs in dividing (activated) T-lymphocytes. Non-dividing resting lymphocytes and macrophages, however, might be long-term reservoirs for HIV-1. We wanted to increase the antiviral efficacy of combination therapies by targeting simultaneously reservoir cells and the virus. Hydroxyurea blocks cellular activation necessary for viral replication in CD4 T-lymphocytes, protease-inhibitors inhibit HIV-1 replication in dividing cells, and hydroxyurea with didanosine is effective in non-dividing cells. 1 Lori F Malykh A Cara A et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994; 266: 801-805 Crossref PubMed Scopus (309) Google Scholar , 2 Perno CF Yarchoan R Cooney DA et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989; 169: 933-951 Crossref PubMed Scopus (251)
No takes yet. Share an insight, caveat, or question.
Lisziewicz et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: